Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial
Sabino De Placido, Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Luca Moscetti(Ospedale di Belcolle), Paolo Carlini(National Cancer Institute), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Grazia Arpino(University of Naples Federico II), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giancarlo Bisagni, Francesco Cognetti(Apple (Israel)), Alessio Aligi Cogoni(Azienda Ospedaliero Universitaria di Sassari), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), D. Amoroso(Ospedale Versilia), Antonio Russo(University of Palermo), Lucio Laudadio(Ospedale "Floraspe Renzetti"), Maria Giuseppa Sarobba(Azienda Ospedaliero Universitaria di Sassari)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830